Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
In Reply: These letters raise interesting issues
and question whether the NCEP-ATP III reached the right decisions on several
aspects of the guidelines. Dr Feeman doubts that primary care physicians will
use Framingham scoring in risk assessment. He proposes an alternate approach
to risk assessment that in our view is even more complex than Framingham scoring.
Moreover, in ATP III, Framingham scoring is added to a familiar risk assessment
approach based on the algorithm used in ATP II. Framingham risk scoring is
added to achieve a more tailored therapy for higher risk patients to ensure
maximal benefit at greatest safety and lowest drug cost.
Grundy SM, Cleeman JI. Guidelines for Diagnosis and Treatment of High Cholesterol—Reply. JAMA. 2001;286(19):2400-2402. doi:10.1001/jama.286.19.2398